Radiation retinopathy treated successfully with aflibercept

Pooprasert, Pakinee; Young-Zvandasara, Tafadzwa; Al‐Bermani, Ayad

doi:10.1136/bcr-2017-220744

Cited by 8 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four studies have documented improvement with aflibercept as a primary treatment for radiation retinopathy. In 2017, Pooprasert et al [35] demonstrated improvement in radiation retinopathy in a single case of radiation retinopathy. In 2019, Karagiannis et al [32] utilized primary intravitreal aflibercept and demonstrated improvement in a patient with bilateral peripheral radiation retinopathy and unilateral maculopathy presumed to be related to external beam radiotherapy of an optic nerve glioma.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, limited information on the use of intravitreal aflibercept has also shown anatomical and functional benefits. Aflibercept is a human recombinant fusion protein that is extensively used for diabetic macular edema, macular degeneration, central and branch retinal vein occlusions, and other sources of neovascularization within the eye [32][33][34][35].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of Second-Line Intravitreal Anti-VEGF Switch Therapy in Radiation Retinopathy Secondary to Uveal Melanoma: Moving from Bevacizumab to Aflibercept

Srivastava

Weis

2022

Ocul Oncol Pathol

View full text Add to dashboard Cite

Introduction: Radiation retinopathy is a dose-dependent complication of the retina following exposure to ionizing radiation. The objective of this prospective case-series is to determine the clinical efficacy of intravitreal aflibercept for radiation retinopathy secondary to radiotherapy for uveal melanoma in those that failed intravitreal bevacizumab treatment. Methods: A case-series of thirty patients with a mean age of 57 ± 15 years with radiation retinopathy were enrolled. Visual acuity (VA) and central foveal thickness (CFT) response to therapy were assessed with regression analyses at one month, three months, and six months following the switch to aflibercept. Results: Regression analyses showed statistically significant reduction in CFT and improvements in VA following the switch to treatment by aflibercept at one month, three months, and six months. The mean CFT improved from 476 μm ± 170 to 386 μm ± 139 and the mean VA improved minimally from 20/115 ± 20/63 to 20/112 ± 20/54 over 6 months. After six months of aflibercept, 46% of patients displayed a CFT improvement of 100 μm or greater and 23% of patients showed improvement in VA of 1 line or better. Conclusion: This pilot study suggests that patients with radiation retinopathy who have failed monthly intravitreal bevacizumab may respond to aflibercept.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Outcomes of Second-Line Intravitreal Anti-VEGF Switch Therapy in Radiation Retinopathy Secondary to Uveal Melanoma: Moving from Bevacizumab to Aflibercept

Srivastava

Weis

2022

Ocul Oncol Pathol

View full text Add to dashboard Cite

show abstract

“…Pooprasert et al16 presented a case in which aflibercept monotherapy was used to treat cystoid macular oedema in a patient with radiation retinopathy.…”

Section: Discussionmentioning

confidence: 99%

<p>Glioma-associated radiation retinopathy treated successfully with aflibercept</p>

Karagiannis

Kontomichos

Georgalas

et al. 2019

TCRM

View full text Add to dashboard Cite

Radiation retinopathy is a chronic, progressive retinal microangiopathy which can occur with variable latency after retina exposure to ionizing radiation used for cancer treatment. It can occur secondary to treatment of nasopharyngeal tumors, as well as intraocular tumors, such as uveal melanoma and retinoblastoma. Several treatment modalities have been reported including intravitreal corticosteroids, intravitreal anti-VEGFs and argon laser photocoagulation. Our purpose is to present a case report of bilateral radiation retinopathy with macular edema in one eye that was revealed 6 years after glioma therapy and treated successfully by using monotherapy of aflibercept. A 59-year-old male patient presented with gradually deteriorating visual acuity in his left eye for the past 12 months. Best corrected visual acuity in his right eye was 20/25 and in his left eye 20/100. Fundoscopy and fluorescein angiography revealed severe non-proliferative retinopathy in his right eye and proliferative retinopathy in his left eye with macular edema. Following complete work-up and due to his past medical history, he was diagnosed with radiation retinopathy. The patient received 6 intravitreal injections of aflibercept in a period of 9 months in order to treat macular edema and radiation retinopathy. According to the literature, there is minimal experience using aflibercept monotherapy to successfully treat macular edema due to radiation retinopathy. In addition, radiotherapy for glioma is a rather rare cause of radiation retinopathy compared to other more common causes, such as nasopharyngeal tumors, meningiomas, and uveal melanomas.

show abstract

“…Photodynamic therapy, consisting of infusion of intravenous verteporfin followed by 689‐nm laser therapy, has been reported to improve visual acuity for radiation maculopathy 35 and neovascularization 36 . Studies of antivascular endothelial growth factor agents, including bevacizumab, 37 ranibizumab, 38 and aflibercept, 39 have shown reduction in macular edema or improved visual acuity. In a prospective study of symptomatic radiation maculopathy after plaque brachytherapy, a single intravitreal injection of triamcinolone, a corticosteroid with angiostatic effect, 40 stabilized or improved visual acuity in 91% of patients at one month and 45% at six months 41 .…”

Section: Ocularmentioning

confidence: 99%

Supportive care for toxicities in children undergoing radiation therapy

Patel

Vargo

Olson

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Radiation therapy (RT) is an integral part of the management of many pediatric tumors; however, it is associated with both acute and permanent adverse events that can significantly impact a child's quality of life, lead to treatment delays, and potentially affect outcomes of cancer therapy. Prevention, early detection, and optimal management of these adverse effects will help reduce their impact on the patients’ quality of life and overall well‐being. Unfortunately, there has not been a coordinated effort to study the etiology, evaluate risk factors, and explore novel treatments for these conditions. Studies of supportive care for children undergoing RT are often small and uncontrolled. This review will focus on the impact of irradiation on the different organ systems and their current management. Further studies are required to improve our understanding of the contributing factors and explore novel treatment options for these adverse effects and to enable children and their families to better cope with some of the unavoidable toxicities following multimodality therapy.

show abstract

Radiation retinopathy treated successfully with aflibercept

Cited by 8 publications

References 6 publications

Outcomes of Second-Line Intravitreal Anti-VEGF Switch Therapy in Radiation Retinopathy Secondary to Uveal Melanoma: Moving from Bevacizumab to Aflibercept

Outcomes of Second-Line Intravitreal Anti-VEGF Switch Therapy in Radiation Retinopathy Secondary to Uveal Melanoma: Moving from Bevacizumab to Aflibercept

<p>Glioma-associated radiation retinopathy treated successfully with aflibercept</p>

Supportive care for toxicities in children undergoing radiation therapy

Contact Info

Product

Resources

About